The merged company will complete the integration of Astra and Zeneca in Japan and strengthen AstraZeneca's business there. AstraZeneca K.K. is a 100 per cent-owned subsidiary of AstraZeneca established by the merger of Astra Japan K.K. and Zeneca K.K. as of January 1, 2000. Zeneca Yakuhin K.K. is a joint venture between AstraZeneca and Sumitomo Kagaku with a shareholding ratio of 60 per cent and 40 per cent, respectively.
AstraZeneca K.K. will be based in Osaka and integrate the assets and employees of Zeneca Yakuhin. The company will have about 2,000 employees and annual sales of about 100 billion yen (at NHI price level).
|
Steve Brown
+44 (0)20 7304 5033
Lucy Williams
+44 (0)20 7304 5034
|
|
|
- The major products of AstraZeneca K.K. will be:
- Cardiovascular - Tenormin, Zestril, Seloken, Splendil.
- Gastrointestinal - Omepral (omeprazole)
- Oncology - Zoladex, Nolvadex, Casodex.
- Anaesthesia - Xylocaine, Diprivan.
|